Military Products Will Get US FDA Fast-Track Review
Executive Summary
FDA and the US Department of Defense launched a program to prioritize development of medical products for use in the battlefield. The program implements recently enacted compromise legislation that resolved a turf battle between the two agencies.
You may also be interested in...
‘State Of HHS’ Speech Highlights Price Transparency, Disaster Response
US Secretary of Health & Human Services Alex Azar discussed the move toward value-based health care, as well as HHS’s role in disaster response, as part of an annual "State of the Department" speech. The speech is tied to the release of HHS’s annual report.
First Concussion Blood Test Leverages De Novo, Breakthrough Pathways
The Banyan Brain Trauma Indicator is the first blood test for detecting concussions in adults to reach the US market and the second device to emerge from US FDA's Breakthrough Devices Program. While test-maker Banyan Biomarkers originally flirted with the PMA pathway, FDA swayed it to the de novo process, which the firm ultimately leveraged to gain the market go-ahead.
FDA Authorizes Emergency Use Of Devices In War Time, Bill Signed By The President Clarifies
President Trump signed off on legislation allowing US FDA to authorize additional emergency uses for medical products to reduce deaths and impacts of injuries caused by "agents of war." The signature ends a turf battle between FDA and the Department of Defense over authorizing products needed quickly under the emergency conditions of war.